Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in sickle cell disease
NL-OMON60198Phase 2Active, not recruiting
- Sponsor
- Julius Clinical
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitapivat in sickle cell disease (SCD), sponsored by Julius Clinical. Primary endpoints: Safety of mitapivat, Change in point of sickling and 1 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON60198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60198.